English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Methods Randomized, open-label, prospective study comparing once-daily ATV/r with twice-daily LPV/r, both with fixeddose TDF/FTC in 883 treatment-naive patients. Treatment outcomes of HIV-RNA <50 c/mL at week 48 using confirmed virologic response (CVR) and grade 2–4 treatmentrelated AEs through week 48 are presented by pre-specified baseline HIV-RNA and CD4 cell count strata. Summary of results The proportion of responders (CVR HIV-RNA <50 c/mL, ITT) at week 48 by baseline HIV RNA strata (<100,000, 100,000–<500,000, and ≥500,000) were 83%, 76%, and 64% for ATV/r and 80%, 74%, and 61% for LPV/r (Table 1).

Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated With atazanavir/r and lopinavir/r in the CASTLE study